Biogen has finalized its acquisition of RayThera Inc., a biotech company specializing in small-molecule therapies for immunology. This deal strengthens Biogen’s immunology portfolio by adding multiple assets aimed at treating immune-related conditions. The lead program from RayThera entered Phase 1 clinical development in July 2026, marking a significant step in Biogen’s strategy to grow its pipeline and invest in immunology as a key area. This acquisition reflects Biogen’s commitment to innovation and long-term growth in the biotech sector.
Biogen presented new 76-week data on EMPAVELI (pegcetacoplan) at the ASN Kidney Week 2026, demonstrating sustained reduction in proteinuria and stabilization of kidney function in patients with rare kidney diseases C3G and primary IC-MPGN. This suppo...
Biogen Inc. will release its third-quarter results on October 28. The company recently raised its full-year 2026 non-GAAP diluted EPS guidance from $15.25-$16.25 to $15.85-$16.85, signaling confidence in its financial outlook. In Q2, Biogen's Alzheim...
